Skip to main content
Top
Published in: Supportive Care in Cancer 12/2016

01-12-2016 | Original Article

Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22

Authors: Rachel McDonald, Keyue Ding, Edward Chow, Ralph M. Meyer, Abdenour Nabid, Pierre Chabot, Genevieve Coulombe, Shahida Ahmed, Joda Kuk, Rashid Dar, Aamer Mahmud, Alysa Fairchild, Carolyn F. Wilson, Jackson S. Y. Wu, Kristopher Dennis, Carlo DeAngelis, Rebecca K. S. Wong, Liting Zhu, Michael Brundage

Published in: Supportive Care in Cancer | Issue 12/2016

Login to get access

Abstract

Purpose

Previous studies have determined optimal cut points (CPs) for the classification of pain severity as mild, moderate, or severe using only the Brief Pain Inventory (BPI) or the BPI in conjunction with a quality of life (QOL) tool. The purpose of our study was to determine the optimal CPs based on correlation with only QOL outcomes.

Methods

We conducted an analysis of 298 patients treated with radiation therapy for painful bone metastases on a phase III randomized trial. Prior to treatment, patients provided their worst pain score on a scale of 0 (no pain) to 10 (worst possible pain), as well as completed the European Organization of Cancer Research and Treatment (EORTC) QOL Questionnaire Bone Metastases module (QLQ-BM22) and the EORTC QOL Questionnaire Core-15 Palliative (QLQ-C15-PAL). Optimal CPs were determined to be those that yielded the largest F ratio for the between category effect on each subscale of the QLQ-BM22 and QLQ-C15-PAL using the multivariate analysis of variance (MANOVA).

Results

The two largest F ratios for Wilk’s λ, Pillai’s Trace, and Hotelling’s Trace were for CPs 5,6 and 5,7. Combining both, the optimal CPs to differentiate between mild, moderate, and severe pain were 5 and 7. Pain scores of 1–5, 6, and 7–10 were classified as mild, moderate, and severe, respectively. Patients with severe pain experienced greater functional interference and poorer QOL when compared to those with mild pain.

Conclusion

Our results suggest that, based on the impact of pain on QOL measures, pain scores should be classified as follows: 1–5 as mild pain, 6 as moderate pain, and 7–10 as severe pain. Optimal CPs vary depending on the type of outcome measurement used.
Literature
2.
3.
go back to reference . Arias F, Arraras JI, Asin G, Zarandona U, Mora I, Errasti M, Barrado M, Campo M, Visus I, Dominguez MA (2015) To what extent does radiotherapy improve the quality of life of patients with bone metastasis? Am J Clin Oncol . Arias F, Arraras JI, Asin G, Zarandona U, Mora I, Errasti M, Barrado M, Campo M, Visus I, Dominguez MA (2015) To what extent does radiotherapy improve the quality of life of patients with bone metastasis? Am J Clin Oncol
4.
5.
go back to reference World Health Organization (1990) Cancer pain relief and palliative care: report of the WHO expert committee on cancer pain relief and active supportive care. Technical Report Series 804, Geneva World Health Organization (1990) Cancer pain relief and palliative care: report of the WHO expert committee on cancer pain relief and active supportive care. Technical Report Series 804, Geneva
6.
go back to reference World Health Organization (1996) Cancer pain relief: with a guide to opioid availability. Geneva World Health Organization (1996) Cancer pain relief: with a guide to opioid availability. Geneva
7.
go back to reference Cancer Care Ontario (2012) Cancer-related pain management. Program in evidence-based care evidence-based series no.: 16–2 [education and information 2011 Sep]. Cancer Care Ontario, Toronto (ON) Cancer Care Ontario (2012) Cancer-related pain management. Program in evidence-based care evidence-based series no.: 16–2 [education and information 2011 Sep]. Cancer Care Ontario, Toronto (ON)
8.
go back to reference Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284CrossRefPubMed Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284CrossRefPubMed
9.
go back to reference Paul SM, Zelman DC, Smith M, Miaskowski C (2005) Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 113(1–2):37–44CrossRefPubMed Paul SM, Zelman DC, Smith M, Miaskowski C (2005) Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 113(1–2):37–44CrossRefPubMed
10.
go back to reference Li KK, Harris K, Hadi S, Chow E (2007) What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 10(6):1338–1346CrossRefPubMed Li KK, Harris K, Hadi S, Chow E (2007) What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 10(6):1338–1346CrossRefPubMed
11.
go back to reference Kalyadina SA, Ionova TI, Ivanova MO, Uspenskaya OS, Kishtovich AV, Mendoza TR, Guo H, Novik A, Cleeland CS, Wang XS (2008) Russian brief pain inventory: validation and application in cancer pain. J Pain Symptom Manag 35(1):95–102CrossRef Kalyadina SA, Ionova TI, Ivanova MO, Uspenskaya OS, Kishtovich AV, Mendoza TR, Guo H, Novik A, Cleeland CS, Wang XS (2008) Russian brief pain inventory: validation and application in cancer pain. J Pain Symptom Manag 35(1):95–102CrossRef
13.
go back to reference . Chow E, Ding K, Parulekar WR, Wong RK, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Nabid A, Ong F, van Tienhoven G, Babington S, Demas WF, Wilson CF, Brundage M, Zhu L, Meyer RM (2015) Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Supp Care Cancer . Chow E, Ding K, Parulekar WR, Wong RK, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Nabid A, Ong F, van Tienhoven G, Babington S, Demas WF, Wilson CF, Brundage M, Zhu L, Meyer RM (2015) Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Supp Care Cancer
14.
go back to reference Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, JS W, Dennis K, Brundage M, DeAngelis C, Wong RK (2015) Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 16(15):1463–1472. doi:10.1016/S1470-2045(15)00199-0 CrossRefPubMed Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, JS W, Dennis K, Brundage M, DeAngelis C, Wong RK (2015) Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 16(15):1463–1472. doi:10.​1016/​S1470-2045(15)00199-0 CrossRefPubMed
15.
go back to reference Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap 23(2):129–138PubMed Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap 23(2):129–138PubMed
16.
go back to reference Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, Wu J, Shafiq J, Sezer O, Kardamakis D, Linden YV, Ma B, Castro M, Arnalot PF, Ahmedzai S, Clemons M, Hoskin P, Yee A, Brundage M, Bottomley A, EORTC Quality of Life Group; Collaboration for Cancer Outcomes Research and Evaluation (2009) The European Organisation for Research and Treatment of Cancer quality of life questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer 45(7):1146–1152. doi:10.1016/j.ejca.2008.11.013 CrossRefPubMed Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, Wu J, Shafiq J, Sezer O, Kardamakis D, Linden YV, Ma B, Castro M, Arnalot PF, Ahmedzai S, Clemons M, Hoskin P, Yee A, Brundage M, Bottomley A, EORTC Quality of Life Group; Collaboration for Cancer Outcomes Research and Evaluation (2009) The European Organisation for Research and Treatment of Cancer quality of life questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer 45(7):1146–1152. doi:10.​1016/​j.​ejca.​2008.​11.​013 CrossRefPubMed
17.
go back to reference Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB, EORTC Quality of Life Group (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42(1):55–64CrossRefPubMed Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB, EORTC Quality of Life Group (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42(1):55–64CrossRefPubMed
Metadata
Title
Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22
Authors
Rachel McDonald
Keyue Ding
Edward Chow
Ralph M. Meyer
Abdenour Nabid
Pierre Chabot
Genevieve Coulombe
Shahida Ahmed
Joda Kuk
Rashid Dar
Aamer Mahmud
Alysa Fairchild
Carolyn F. Wilson
Jackson S. Y. Wu
Kristopher Dennis
Carlo DeAngelis
Rebecca K. S. Wong
Liting Zhu
Michael Brundage
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3341-9

Other articles of this Issue 12/2016

Supportive Care in Cancer 12/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine